Predictive Pharmacokinetics and Pharmacodynamics
We integrate in vitro, in vivo and clinical data through PKPD-modelling with the ultimate goal to optimize dosing in patients. Our focus is on efficient development of antibiotics and therapies against cancer.
We apologise for the limited content. The homepage is under construction.
If you have any questions, please contact the research group leader: Lena Friberg
Contact all group members: Research group predictive PKPD
News
- Greta Hultqvist receives SEK 1M from the Alzheimer's Foundation
- Sweden Inhalation Network unites Swedish expertise in pulmonary drug delivery
- DRUGtrain explores drug repurposing to find treatment for ADPKD
- Alexandra Teleki new member of the Particle Technology Forum (AIChE) executive committee
- Vinnova praises SweDeliver in new evaluation
Kalendarium
- Unfortunately there are no upcoming events at this time
Publikationer
-
Yin, Anyue; van Hasselt, Johan G. C.; Guchelaar, Henk-Jan; Friberg, Lena; Moes, Dirk Jan A. R.
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
2022
-
Arrazuria, Rakel; Kerscher, Bernhard; Huber, Karen E.; Hoover, Jennifer L.; Lundberg, Carina Vingsbo; Hansen, Jon Ulf; Sordello, Sylvie; Renard, Stephane; Aranzana-Climent, Vincent; Hughes, Diarmaid; Gribbon, Philip; Friberg, Lena; Bekeredjian-Ding, Isabelle
Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections
2022
-
Nutman, Amir; Temkin, Elizabeth; Lellouche, Jonathan; Rakovitsky, Nadya; Hameir, Amichay; Daikos, George; Durante-Mangoni, Emanuele; Pavleas, Ioannis; Dishon, Yael; Petersiel, Neta; Yahav, Dafna; Eliakim, Noa; Bernardo, Mariano; Iossa, Domenico; Friberg, Lena; Theuretzbacher, Ursula; Leibovici, Leonard; Paul, Mical; Carmeli, Yehuda
In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
2022